Neoleukin Therapeutics, Inc.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: US64049K1043

USD

21.16

1.92 (9.98%)

Dec 04

NAS

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

CorMedix, Inc.

Poseida Therapeutics, Inc.

Invivyd, Inc.

Lineage Cell Therapeutics, Inc.

Foghorn Therapeutics, Inc.

Fate Therapeutics, Inc.

Verastem, Inc.

Taysha Gene Therapies, Inc.

Vigil Neuroscience, Inc.

Neoleukin Therapeutics, Inc.

Synlogic, Inc.

Why is Neoleukin Therapeutics, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Neoleukin Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Neoleukin Therapeutics, Inc.

-5.28%

-0.36

132.12%

S&P 500

13.22%

0.96

19.87%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-186.08%

EBIT to Interest (avg)

-60.78

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.99

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

92.47%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.57

EV to EBIT

-1.88

EV to EBITDA

-1.95

EV to Capital Employed

73.99

EV to Sales

168.47

PEG Ratio

Dividend Yield

ROCE (Latest)

-3941.37%

ROE (Latest)

-27.71%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Sideways

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET PROFIT(HY)

Higher at USD -44.66 MM

CASH AND EQV(HY)

Highest at USD 567.12 MM

EPS(Q)

Highest at USD -1.05

-6What is not working for the Company

NET PROFIT(HY)

At USD -44.66 MM has Grown at -26.12%

RAW MATERIAL COST(Y)

Grown by 109.36% (YoY

OPERATING PROFIT(Q)

Lowest at USD -25.27 MM

Here's what is working for Neoleukin Therapeutics, Inc.

Net Profit

Higher at USD -44.66 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

EPS

Highest at USD -1.05

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv

Highest at USD 567.12 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Here's what is not working for Neoleukin Therapeutics, Inc.

Net Profit

At USD -44.66 MM has Grown at -26.12%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Operating Profit

Lowest at USD -25.27 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Raw Material Cost

Grown by 109.36% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales